Valuation: Insulet Corporation

Market Cap 11.36B 9.93B 9.16B 8.45B 15.92B 1,094B 16.27B 110B 43.08B 536B 42.68B 41.74B 1,845B P/E 2026 *
26.5x
P/E 2027 * 20.6x
Enterprise Value 11.44B 10B 9.22B 8.5B 16.03B 1,102B 16.38B 110B 43.37B 540B 42.96B 42.02B 1,857B EV / Sales 2026 *
3.45x
EV / Sales 2027 * 2.82x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day-0.23%
1 week+1.72%
Current month+7.76%
1 month+14.31%
3 months-19.47%
6 months-42.98%
Current year-42.28%
1 week 153.84
Extreme 153.84
169.85
1 month 138.79
Extreme 138.79
169.85
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Chief Operating Officer 43 25/08/2025
Director TitleAgeSince
Director/Board Member 59 10/08/2017
Chairman 61 01/01/2019
Director/Board Member 66 04/02/2022
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Other

Director

0 0%
01/07/26 Free

Director

1,355 0.0019%
30/06/26 Free

Director

151 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%+1.72%-42.12%-43.03% 11.36B
+1.87%+7.19%-16.46%-5.91% 175B
-0.43%-0.80%-7.07%-4.05% 106B
-0.03%+1.47%+4.59%+60.25% 59.91B
+0.66%+0.96%+37.56%+53.38% 51.95B
-1.10%+4.10%-12.56%-38.37% 43.58B
-3.21%-3.05% - - 33.65B
-1.71%+2.25%-8.86%-44.23% 29.58B
-1.16%+1.28%+61.67%-6.62% 25.31B
-1.49%+0.85%-3.01%-4.60% 21.23B
Average -0.68%+1.81%+1.53%-3.69% 55.84B
Weighted average by Cap. +0.08%+2.78%-2.29%+2.25%

Financials

2026 *2027 *
Net sales 3.32B 2.9B 2.68B 2.47B 4.65B 320B 4.75B 32B 12.59B 157B 12.47B 12.19B 539B 3.93B 3.43B 3.17B 2.92B 5.5B 378B 5.62B 37.85B 14.89B 185B 14.75B 14.42B 638B
Net income 432M 378M 348M 321M 605M 41.61B 619M 4.16B 1.64B 20.38B 1.62B 1.59B 70.15B 564M 493M 455M 419M 790M 54.33B 808M 5.44B 2.14B 26.61B 2.12B 2.07B 91.6B
Net Debt 75.17M 65.69M 60.61M 55.87M 105M 7.24B 108M 724M 285M 3.55B 282M 276M 12.2B -283M -247M -228M -210M -396M -27.25B -405M -2.73B -1.07B -13.34B -1.06B -1.04B -45.94B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
17/07/26 $164.06 -0.23% 1,396,164
16/07/26 $164.43 +3.23% 1,498,524
15/07/26 $159.28 +0.10% 1,332,050
14/07/26 $159.12 -1.81% 1,942,227
13/07/26 $162.06 +0.48% 1,616,899
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
164.06USD
Average target price
238.22USD
Spread / Average Target
+45.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock